Poster can be found in location 62.

Patient representatives are crucial to ensuring that patients are involved in health research and development, thereby improving health services. However, the role of patient representatives and collaboration between stakeholders, levels of trust as well and experienced barriers are poorly understood. This pilot survey is part of a larger project that aims to explore patient and public involvement in health research and development using the launch of EUPATI (European Patients Academy on Therapeutic Innovation) Sweden as a case. Aim: To explore patient representatives´ views on their role in health research and development. Methods and Materials: 30 patient representatives were recruited through EUPATI. Participants were asked to rate statements on their role in health research, collaboration between different stakeholders, general understanding of the role of patient in collaboration with other stakeholders in health research and development and trust between different stakeholders and barriers to patient involvement on a scale of 1-5 (1=not important and 5=extremely important). Result and conclusion: The majority of participants were over 40 years old and predominantly female (70%). Most participants possessed post-secondary education qualifications (83%) and had affiliations with patient organizations (82%). They highly valued involvement in roles such as educating healthcare professionals (90%), advising within the healthcare system and research (89%), and advising regulatory agencies and decision-makers (86%). Patient representatives played vital roles in organizations and research and clinical trials (89%). They often collaborated with other patient groups (97%) and healthcare professionals (90%), but interactions with health sector procurement officers/purchaser were infrequent (6%). Participants were most positive about working with researchers (60%) and healthcare professionals (55%) and had high trust levels in them (90% and 70%, respectively). Areas needing more knowledge included drug and medical technology development, regulations, ethical guidelines for patient participation, and collaboration. Further studies will be carried out in autumn to better understand other stakeholders' views on patient involvement including barriers and facilitators.